The Abu Dhabi health care company M42 is to make an investment in U.K.-based longevity specialist Juvenescence as a route to moving into drug discovery and development, with the two forming a partnership to work together on products that extend the healthy lifespan and improve the treatment of chronic diseases.
Stem cell implantation is a step closer to becoming the next strategy against Parkinson's disease. Two clinical trials, one in phase I and the other in phase I/II, have demonstrated their safety and potential to restore dopamine production in the brains of patients with this currently incurable neurodegenerative condition. The number of participants in the study is still small, and further research is needed to demonstrate the clinical benefits of these cell therapies.
Genes associated with lysosomal dysfunction increase the risk of Parkinson’s disease (PD), according to a study led by scientists at Northwestern University. The discovery also explains why some people who carry a pathogenic variant of the GBA1 gene develop PD or dementia with Lewy bodies (DLB) and others do not. The key lies in the Commander complex, involved in the transport of proteins to this organelle. This discovery raises the need for combinatorial therapies that act on more than one pathway for this type of neurodegenerative disorder.